TG Therapeutics, Inc. (TGTX) Stock

Understand TG Therapeutics, Inc.: how it makes money

TG Therapeutics markets Briumvi, an IV infusion antibody for relapsing multiple sclerosis, and earns product revenue from each filled U.S. prescription. Growth is almost entirely a function of new patient starts and payor coverage expanding, backed by patent life into the 2040s but facing a competitive anti-CD20 field.

Every dollar of growth rides on converting payor coverage into filled Briumvi infusions; the product is the company, and repetition (new starts, persistence) is the only growth lever until the pipeline adds a second engine.

Business quality (Strong): Strong revenue growth (70% YoY) and a high gross margin (84%), but operating margin sits at 17% because a single product carries disproportionate R&D, sales, and now manufacturing costs. The business is high-quality at the top line and still proving profitability at the bottom.

Valuation: At 19× earnings, TGTX trades 11% above the Pharmaceutical Products average (17×).

Bull case

• U.S. revenue accelerating: Management reported U.S. revenue grew 17% sequentially and more than 64% year over year in Q2 FY26, showing the new-patient pipeline is still converting quickly into recurring infusion revenue.
• Patent moat runs to the 2040s: Management confirmed patent protection extends into the 2040s, giving well over a decade of exclusivity for Briumvi and limiting near-term generic erosion of the revenue base.
• Growth premium is modest: At a P/E of 19.1 times versus the Pharmaceutical Products industry average of 17.2 times (11% above), the market is charging only a small premium for 70% revenue growth and an 84% gross margin, leaving room for re-rating if execution holds.

Bear case

• Manufacturing costs hit hard: Management guided that manufacturing activities will add approximately $100 million to 2026 expenses. Against quarterly revenue of about $200 million, that single cost line erodes the 17% operating margin materially before any organic improvement.
• Roche entering the field: The anti-CD20 and MS treatment market remains competitive, and management specifically flagged Roche's new formulation as a headwind. If payors or physicians shift even a modest share to a competitor, the single-product revenue model has no buffer.
• Thin operating leverage today: An 84% gross margin collapses to a 17% operating margin, meaning roughly two-thirds of every revenue dollar is consumed by R&D, SG&A, and now manufacturing. Until the revenue base scales further, the profit pool remains narrow and sensitive to any cost overage.

TG Therapeutics, Inc. earnings call transcripts

• TGTX Q2 FY26 earnings call transcript (reported 2026-08-03) · analysis
• TGTX Q4 FY25 earnings call transcript (reported 2026-02-26) · analysis
• TGTX Q2 FY25 earnings call transcript (reported 2025-08-04) · analysis

All TGTX earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Insmed Incorporated (INSM)
• Mirum Pharmaceuticals, Inc. (MIRM)
• BridgeBio Pharma, Inc. (BBIO)
• Travere Therapeutics, Inc. (TVTX)
• Emergent BioSolutions Inc. (EBS)
• Opko Health, Inc. (OPK)
• Catalyst Pharmaceuticals, Inc. (CPRX)
• Ionis Pharmaceuticals, Inc. (IONS)